1099-0496/asset/PPUL_left.gif?v=1&s=e8619a3cee0d6c89bf229cccb87c45f4fc06ef2f)
1099-0496/asset/PPUL_centre.gif?v=1&s=50c62acecf2eca9b4984459eb3e50e4cd8914b61)
Case Report
Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis
Article first published online: 4 FEB 2002
DOI: 10.1002/ppul.10062
Copyright © 2002 Wiley-Liss, Inc.
1099-0496/asset/cover.gif?v=1&s=5de05e31550258bf0b9d3a03f2c45dcc5812a5a1 "Pediatric Pulmonology")
Additional Information
How to Cite
Ferrin, M., Zuckerman, J. B., Meagher, A. and Blumberg, E. A. (2002), Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatric Pulmonology, 33: 221–223. doi: 10.1002/ppul.10062
Publication History
- Issue published online: 4 FEB 2002
- Article first published online: 4 FEB 2002
- Manuscript Accepted: 23 FEB 2001
- Manuscript Received: 17 OCT 2000
- Abstract
- References
- Cited By
Keywords:
- cystic fibrosis;
- methicillin-resistant Staphylococcus aureus;
- linezolid
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of pulmonary infection in patients with cystic fibrosis (CF). Because these organisms are frequently multidrug-resistant, most patients require intravenous therapy with vancomycin. We report on the first case of successful treatment of a pulmonary exacerbation due to MRSA in a CF patient with a new antimicrobial, linezolid. We demonstrated equivalence of intravenous and oral dosing in this patient, suggesting that oral linezolid may be an excellent alternative to intravenous vancomycin for CF patients infected with MRSA. Pediatr Pulmonol. 2002; 33:221–223. © 2002 Wiley-Liss, Inc.